![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Eli Lilly Ordered to Pay Teva Approximately $176.5 Million in Damages
Eli Lilly Ordered to Pay Teva Approximately $176.5 Million in Damages
A federal jury in Massachusetts has decided that Eli Lilly must pay Teva Pharmaceuticals approximately $176.5 million in damages over infringement of three patents covering Teva’s migraine treatment Ajovy (fremanezumab-vfrm).
Teva filed a complaint in a U.S. District Court in Massachusetts in September 2018 accusing Lilly of violating the patents with Emgality (galcanezumab-gnlm), which is FDA-approved for the preventive treatment of migraine in adults.
Teva filed a second lawsuit concerning patent infringement by Emgality in June 2021 which is ongoing.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct